Literature DB >> 2729954

Increasing rates of in vitro resistance to ciprofloxacin and norfloxacin in isolates from urine specimens.

D Desgrandchamps, J Munzinger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2729954      PMCID： PMC172491          DOI： 10.1128/AAC.33.4.595-b

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  11 in total

1.  Susceptibility of Hong Kong isolates of methicillin-resistant Staphylococcus aureus to antimicrobial agents.

Authors:  G L French; J Ling; T Ling; Y W Hui
Journal:  J Antimicrob Chemother       Date:  1988-05       Impact factor: 5.790

2.  Comparison of the Cobas-Bact five-hour susceptibility testing system with the NCCLS agar diffusion and dilution methods.

Authors:  J Wüst; W Heizmann; U Hardegger; B Manncke
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

3.  Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.

Authors:  A L Barry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

4.  Oral ciprofloxacin in resistant urinary tract infections.

Authors:  J L Ryan; C S Berenson; T P Greco; R J Mangi; M Sims; G F Thornton; V T Andriole
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

5.  In-vitro selection of bacteria resistant to the 4-quinolone agents.

Authors:  D I Limb; D J Dabbs; R C Spencer
Journal:  J Antimicrob Chemother       Date:  1987-01       Impact factor: 5.790

6.  Ciprofloxacin therapy in complicated urinary tract infections caused by Pseudomonas aeruginosa and other resistant bacteria.

Authors:  D A Leigh; F X Emmanuel; V J Petch
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

7.  Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin.

Authors:  M Kresken; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

8.  Ciprofloxacin therapy of respiratory tract infection with Pseudomonas aeruginosa.

Authors:  M J Haverkorn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-10       Impact factor: 3.267

9.  Comparison of ciprofloxacin and co-trimoxazole in the treatment of uncomplicated urinary tract infection in women.

Authors:  N K Henry; H J Schultz; N C Grubbs; S M Muller; D M Ilstrup; W R Wilson
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

10.  Evaluation of the Cobas Bact automated system for susceptibility testing of Enterobacteriaceae, Pseudomonas aeruginosa, and Enterococcus faecalis to azlocillin, mezlocillin, and ciprofloxacin compared to NCCLS and DIN standards.

Authors:  W Heizmann; H Werner; F Heilmann
Journal:  Infection       Date:  1988       Impact factor: 3.553
View more
  3 in total

1.  Increasing incidence of Corynebacterium group D2 strains resistant to norfloxacin and ciprofloxacin.

Authors:  F Soriano; R Fernández-Roblas; J Zapardiel; J L Rodríguez-Tudela; P Avilés; M Romero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

2.  Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy.

Authors:  J M Diver; T Schollaardt; H R Rabin; C Thorson; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

3.  Outpatient Antibiotic Consumption for Urinary Infections in Croatia 2005 - 2014: What can be Learned from Utilization Trends.

Authors:  Željko Vojvodić; Danijela Daus Šebeđak
Journal:  Zdr Varst       Date:  2018-10-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.